O-RADS US
- Lexicon: smooth/irregular refers to the inner wall or septations of cystic lesions and the outer contour of solid lesions; irregular inner wall = <3 mm in height. A solid component protrudes ≥3 mm; a solid lesion is ≥80% solid (excluding blood products and dermoid contents). Shadowing must be diffuse or broad (not refractive artifact).
- Management recommendations are guidance for average-risk patients without acute symptoms; they may be modified for personal or family history of ovarian cancer, BRCA mutation, symptoms, and clinical judgment.
- MRI with contrast has higher specificity for solid lesions and cystic lesions with solid components; O-RADS MRI can problem-solve O-RADS US 3–4 lesions.
- The simple-cyst intervals here are O-RADS US v2022. The SRU 2019 simple-cyst consensus (`adnexal-cyst-us`) uses different thresholds and visualization-dependent intervals.
- 1Check that O-RADS applies: not for pelvic inflammatory disease, ectopic pregnancy, torsion of a normal ovary, or lesions clearly non-ovarian/non-tubal (for example, an exophytic or broad-ligament myoma). Absent or non-visualized ovaries are “O-RADS: not applicable”; use O-RADS 0 when an expected ovary is not seen or technical factors prevent assessment of features relevant to risk.
- 2Use the single largest diameter for scoring and management (report three dimensions; average linear dimension for interval change). Assess transvaginally where possible.
- 3No ovarian lesion, or a follicle (≤3 cm) or corpus luteum (typically ≤3 cm) → O-RADS 1.
- 4Typical classic benign lesion (hemorrhagic cyst, dermoid, endometrioma) <10 cm, or a typical extraovarian lesion (paraovarian cyst, peritoneal inclusion cyst, hydrosalpinx) of any size → O-RADS 2, managed per the classic benign lesions table. A typical benign ovarian lesion ≥10 cm → O-RADS 3.
- 5Otherwise classify the lesion type: unilocular (no septation), bilocular (one complete septation, 2 locules), multilocular (≥3 locules), cystic with solid component(s), or solid (≥80% solid). Note smooth vs irregular inner wall (cystic) or outer contour (solid), papillary projections (solid component ≥3 mm into the lumen, surrounded by fluid on 3 sides), and shadowing (diffuse or broad).
- 6Assign the color score: 1 no flow, 2 minimal, 3 moderate, 4 very strong.
- 7Map to the category using the descriptors below. If unsure between two features (for example, smooth vs irregular, or color score), use the higher-risk category. With multiple or bilateral lesions, characterize each; management follows the highest score.
- 8Menopausal status: postmenopausal = amenorrhea ≥1 year (early <5 years, late ≥5 years). If uncertain or no uterus, treat age >50 as postmenopausal (early >50 to <55, late ≥55).
Repeat US study or MRI.
O-RADS US 0. Incomplete evaluation because of technical factors. Recommend repeat ultrasound or MRI.
None.
O-RADS US 1. Normal ovary. No follow-up is needed.
Simple cyst: ≤3 cm none; >3–5 cm none (premenopausal) or follow-up US in 12 months (postmenopausal); >5 to <10 cm follow-up US in 12 months. Unilocular smooth non-simple or bilocular smooth cyst: ≤3 cm none (premenopausal) or follow-up US in 12 months (postmenopausal); >3 to <10 cm follow-up US in 6 months. Classic benign lesions: see the classic benign lesions table. If the cyst shrinks by ≥10–15% in average linear dimension, no further surveillance; if stable, consider US at 24 months from the initial exam.
O-RADS US 2 (almost certainly benign, <1% risk of malignancy). Management per lesion type, size, and menopausal status.
Imaging: if not surgically excised, consider follow-up US within 6 months; if solid, may consider a US specialist or MRI (with O-RADS MRI score). Clinical: gynecologist.
O-RADS US 3 (low risk, 1 to <10% risk of malignancy). If not surgically excised, consider follow-up ultrasound within 6 months. Gynecology management.
Imaging options: US specialist (if available), MRI (with O-RADS MRI score), or per gyn-oncologist protocol. Clinical: gynecologist with gyn-oncologist consultation, or gyn-oncologist alone.
O-RADS US 4 (intermediate risk, 10 to <50% risk of malignancy). Recommend further evaluation by an ultrasound specialist or MRI with O-RADS MRI scoring, and gynecologic oncology involvement.
Imaging: per gyn-oncologist protocol. Clinical: gyn-oncologist.
O-RADS US 5 (high risk, ≥50% risk of malignancy). Recommend gynecologic oncology referral.
Sources
- Strachowski LM, et al. O-RADS US v2022: An Update from the American College of Radiology's Ovarian-Adnexal Reporting and Data System US Committee. Radiology. 2023;308(3):e230685.
Educational reference for clinicians — not medical advice. Verify against the primary source before acting on it; guidelines change. Final decisions rest with the interpreting physician and your institution's protocols.